DK0692970T3 - Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli - Google Patents

Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli

Info

Publication number
DK0692970T3
DK0692970T3 DK94914023T DK94914023T DK0692970T3 DK 0692970 T3 DK0692970 T3 DK 0692970T3 DK 94914023 T DK94914023 T DK 94914023T DK 94914023 T DK94914023 T DK 94914023T DK 0692970 T3 DK0692970 T3 DK 0692970T3
Authority
DK
Denmark
Prior art keywords
actin
contents
pathological
viscosity
sludge
Prior art date
Application number
DK94914023T
Other languages
English (en)
Inventor
Thomas P Stossel
Stuart E Lind
Paul A Janmey
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK0692970T3 publication Critical patent/DK0692970T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94914023T 1993-04-02 1994-04-04 Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli DK0692970T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/042,247 US5464817A (en) 1990-04-11 1993-04-02 Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
PCT/US1994/003667 WO1994022465A1 (en) 1993-04-02 1994-04-04 Method for reducing the viscosity of pathological mucoid airway contents in the respiratoy tract

Publications (1)

Publication Number Publication Date
DK0692970T3 true DK0692970T3 (da) 1999-12-06

Family

ID=21920852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94914023T DK0692970T3 (da) 1993-04-02 1994-04-04 Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli

Country Status (17)

Country Link
US (2) US5464817A (da)
EP (1) EP0692970B1 (da)
JP (2) JPH08510998A (da)
KR (1) KR100308679B1 (da)
CN (1) CN1107521C (da)
AT (1) ATE182790T1 (da)
AU (1) AU695033B2 (da)
BR (1) BR9405856A (da)
CA (1) CA2159205A1 (da)
DE (1) DE69419907T2 (da)
DK (1) DK0692970T3 (da)
ES (1) ES2135576T3 (da)
GB (1) GB2293102B (da)
GR (1) GR3031753T3 (da)
NO (1) NO953862D0 (da)
SG (1) SG49574A1 (da)
WO (1) WO1994022465A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
AU720635B2 (en) * 1995-02-24 2000-06-08 Genentech Inc. Human DNase I variants
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
PT854927E (pt) * 1995-10-10 2008-09-08 Genentech Inc Variantes da adnase i humana
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
EP0941108B1 (en) 1996-12-04 2002-10-16 Renovo Limited Wound healing and treatment of fibrosis
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
CN1329078C (zh) * 2001-12-28 2007-08-01 阿斯比奥制药株式会社 造血干细胞和/或造血前体细胞的增殖和/或分化促进剂
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
RU2269359C2 (ru) * 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
WO2005004904A1 (en) * 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants)
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005046454A2 (en) * 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
KR101314461B1 (ko) * 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
EP1791566A4 (en) 2004-08-06 2008-07-16 Nat Jewish Med & Res Center PRODUCT AND METHOD FOR INHIBITING BIOFILM DEVELOPMENT
EP1880733A4 (en) * 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Method for increasing longevity of a human being and animals
EP3279663B1 (en) 2006-03-15 2021-07-28 The Brigham and Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
CA2680333C (en) * 2006-03-15 2016-10-25 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
KR20090087095A (ko) * 2006-11-28 2009-08-14 드미트리 드미트리에비치 겐킨 조직의 세포외공간에서 증가된 데옥시리보핵산 함량과 관련된 인간 질병을 치료하는 방법 및 이 방법을 수행하기 위한 약학 제제
US8753662B2 (en) * 2007-02-15 2014-06-17 National Jewish Health Methods and compositions for the disruption of biofilms
DK2250280T3 (da) 2008-01-25 2015-03-09 Gen Hospital Corp Terapeutiske anvendelser af gelsolin ved nyreinsufficiens
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DK0526544T3 (da) * 1990-04-11 1999-06-21 Brigham & Womens Hospital Terapeutiske anvendelser af actinbindende forbindelser
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis

Also Published As

Publication number Publication date
DE69419907T2 (de) 1999-12-09
EP0692970B1 (en) 1999-08-04
ATE182790T1 (de) 1999-08-15
AU695033B2 (en) 1998-08-06
GR3031753T3 (en) 2000-02-29
JP2001302537A (ja) 2001-10-31
GB2293102A (en) 1996-03-20
ES2135576T3 (es) 1999-11-01
GB2293102B (en) 1996-10-09
WO1994022465A1 (en) 1994-10-13
BR9405856A (pt) 1996-03-05
KR100308679B1 (ko) 2001-11-30
CA2159205A1 (en) 1994-10-13
NO953862L (no) 1995-09-29
SG49574A1 (en) 1998-06-15
NO953862D0 (no) 1995-09-29
US5656589A (en) 1997-08-12
CN1122108A (zh) 1996-05-08
GB9520020D0 (en) 1995-12-06
AU6625094A (en) 1994-10-24
CN1107521C (zh) 2003-05-07
DE69419907D1 (de) 1999-09-09
US5464817A (en) 1995-11-07
EP0692970A1 (en) 1996-01-24
JPH08510998A (ja) 1996-11-19

Similar Documents

Publication Publication Date Title
GB2293102B (en) Use of actin-binding compounds for reducing the viscosity of pathalogical mucoid airway contents in the respiratory tract
DE69130289D1 (de) Therapeutische verwendung von actin-bindenden verbindungen
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
Folin et al. Some observations on “emotional glycosuria” in man
PT750509E (pt) Utilizacao de il-12 e antagonistas de il-12 para o fabrico de uma composicao farmaceutica para o tratamento de doencas auto-imunes
BR9800846A (pt) Composição de correia de alto módulo e correias fabricadas com a mesma.
BR9809951A (pt) Método para tratamento da obesidade
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
BR9811744A (pt) Conjugados contendo o homeodomìnio de antenapédia
BR0209177A (pt) Anticorpo especìfico a tumor recombinante e uso do mesmo
ATE233096T1 (de) Zusammensetzungen und methoden zur steigerung der darmfunktion
DE69738138D1 (de) Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
BR9711573A (pt) Pepetìdeos c da insulina.
DK93890D0 (da) Syreresistent fgf-praeparat og fremgangsmaade til behandling af ulcererende sygdomme i mave-tarmkanalen
DE69731479D1 (de) Von filaggrin abgeleitete antigene und deren anwendung in der diagnose von rheumatischer polyarthritis
DE69331045D1 (de) Verwendung von igf-1
ATE488250T1 (de) Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
ATE258797T1 (de) Verwendung von amifostin
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE349225T1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
DK0972032T3 (da) Peptider til behandling af systemisk lupus erythematosus
DE69824166D1 (de) Verwendung von vogel-antikörpern
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
BR9510323A (pt) Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica